[1] 侯景贵. 肝小静脉闭塞病——附二例报告.中华内科杂志. 1980,19: 187-191.
[2] Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol, 2003,39: 437-446.
[3] 朱柏任, 濮社班, 徐德然, 等. 菊三七属植物化学成分及药理作用的研究进展. 中国野生植物资源, 2012,31: 1-4.
[4] Edgar JA, Molyneux RJ, Colegate S M. Pyrrolizidine Alkaloids: Potential Role in the Etiology of Cancers, Pulmonary Hypertension, Congenital Anomalies, and Liver Disease. Chem Res Toxicol, 2015,28: 4-20.
[5] 陈磊, 王津江, 宋洪涛, 等. 菊三七属植物化学成分和药理作用研究进展. 中草药, 2009,40: 666-669.
[6] Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol, 2011,54: 666-673.
[7] Wang X, Qi X, Guo X. Tusanqi-Related Sinusoidal Obstruction Syndrome in China: A Systematic Review of the Literatures. Medicine, 2015,94: e942.
[8] 周燕萍, 孙李建, 于珊珊, 等. 土三七引起肝静脉闭塞性疾病并致死亡. 药物不良反应杂志, 2012,14: 327-328.
[9] Fu PP, Chou MW, Churchwell M, et al. High-performance liquid chromatography electrospray ionization tandem mass spectrometry for the detection and quantitation of pyrrolizidine alkaloid-derived DNA adducts in vitro and in vivo. Chem Res Toxicol, 2010,23: 637-652.
[10] Yang M, Ruan J, Fu PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact, 2016,243:119-126.
[11] Sternlicht MD, Werb Z. How matrix met alloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 2001,17: 463-516.
[12] Visse R. Matrix Met alloproteinases and Tissue Inhibitors of Met alloproteinases: Structure, Function, and Biochemistry. Circulation Research, 2003,92: 827-839.
[13] LD D, XW, JT, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix met alloproteinase inhibition. Gastroenterology, 2003,125: 882-890.
[14] 冀涛. MMP-9在土三七致肝窦阻塞综合征中的表达及意义. 浙江大学, 2009.
[15] Sessa WC. The Nitric Oxide Synthase Family of Proteins. J VASC RES, 1994,31: 131-143.
[16] 杜洪涛. 土三七致肝脏损伤机制初步研究. 徐州医学院 徐州医科大学影像医学与核医学, 2013.
[17] Conotte R, Colet JM. A metabonomic evaluation of the monocrotaline-induced sinusoidal obstruction syndrome (SOS) in rats. Toxicol Appl Pharmacol, 2014,276: 147-156.
[18] Li YH, Tai W C, Xue JY, et al. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats. Chem Res Toxicol, 2015,28: 1715-1727.
[19] 方军伟, 张智勤, 潘锦辉, 等. 土三七致肝小静脉闭塞病的血小板及凝血功能临床表现分析. 中国现代应用药学, 2015,32: 874-875.
[20] 郝俊贵, 颜学兵, 季芳. 土三七致肝小静脉闭塞病25例临床特点分析. 肝脏, 2017,22: 108-110.
[21] 方军伟, 张国华, 滕显木, 等. 土三七致肝小静脉闭塞大鼠模型中血液系统毒性和血管内皮分泌功能的观察研究. 中华肝脏病杂志, 2015,23: 59-63.
[22] 陈哲, 霍继荣, 朱洪怡, 等. 川芎嗪对土三七诱导的肝小静脉闭塞病小鼠肝组织PAI-1表达的影响. 中国医科大学学报, 2012,41: 709-712.
[23] 陈华忠, 邵辉, 耿才正, 等. 肝脏影像学检查在土三七引起的肝小静脉闭塞性疾病中的诊断价值. 临床肝胆病杂志, 2012,28: 376-379.
[24] Gao H, Ruan J Q, Chen J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. DRUG DES DEV THER, 2015,9(default):4861-4868.
[25] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017,37: 1627-1637.
[26] 钟岚, 张一. 土三七所致肝小静脉闭塞病142例治疗的临床分析. 医学与哲学(B), 2012,33: 38-40.
[27] 彭俏, 贺德志, 李建生. 肝小静脉闭塞病的临床现状及研究进展. 世界华人消化杂志, 2012: 1030-1035.
[28] Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant, 2008,41: 229-237.
[29] 王轶, 张峰, 张明, 等. 经颈静脉肝内门腔静脉分流术治疗误服土三七后肝小静脉闭塞所致顽固性腹水的疗效. 世界华人消化杂志, 2015: 4261-4265.
[30] 李建平, 胡明华, 金慧涵, 等. 原位肝移植术治疗肝小静脉闭塞病. 中华肝胆外科杂志, 2001,7: 1. |
